# US 2026/0077062 A1 · Antibody gene therapy for treatment and prevention of infection by rabies lyssavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077062 A1
- Document ID: US20260077062A1
- Status: Published application
- Kind: A1
- Application number: 19/200,508
- Filed: 2025-05-06
- Published: 2026-03-19
- Earliest claimed: 2019-09-17
- Assignees: Auburn University
- Applicants: Auburn University; The University of Massachusetts
- Inventors: Henry J. BAKER; Douglas R. MARTIN; Miguel SENA-ESTEVES; Kent R. VAN KAMPEN
- Web page: https://patentgrep.com/patent/US20260077062A1

## CPC

- C07K 16/10: RNA viruses
- A61K 39/12: Viral antigens
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 31/14: for RNA viruses
- C12N 15/86: Viral vectors
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are compositions, vectors, and methods for treating and preventing rabies lyssavirus infection in a subject in need thereof, including rabies lyssavirus encephalitis. The disclosed compositions relate to anti-rabies immunoglobulins and vectors for expressing anti-rabies immunoglobulins such as adeno-associated virus (AAV) vectors that express anti-rabies immunoglobulins in a subject in need thereof. In some embodiments, the disclosed methods relate to treating and/or preventing an infection by rabies lyssavirus in a subject in need thereof, the methods comprising administering to the subject a dose of an adeno-associated virus (AAV) vector that expresses an immunoglobulin that binds and neutralizes rabies lyssavirus in the subject.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method for treating and/or preventing an infection by rabies lyssavirus in a subject in need thereof, the method comprising administering to the subject a dose of an adeno-associated virus (AAV) vector, wherein the AAV vector encodes SEQ ID NO: 1.

### Claim 31 (depends on 30)

The method of claim 30, wherein the rabies lyssavirus infection is encephalitis.

### Claim 32 (depends on 30)

The method of claim 30, wherein the AAV vector expresses systemically in the subject an immunoglobulin that includes the CR57 rabies variable heavy chain region and variable light chain region.

### Claim 33 (depends on 30)

The method of claim 30, wherein the AAV vector expresses in the nervous system of the subject an immunoglobulin that includes the CR57 rabies variable heavy chain region and variable light chain region and has neutralizing activity to rabies lyssavirus.

### Claim 34 (depends on 33)

The method of claim 33, wherein the AAV vector expresses SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region in the central nervous system and/or in the peripheral nervous system of the subject.

### Claim 35 (depends on 30)

The method of claim 30, wherein the AAV vector is administered via a route selected from the group consisting of intravenously, intramuscularly, subcutaneously, orally, or nasally.

### Claim 36 (depends on 30)

The method of claim 30, wherein the AAV vector is administered to the subject at a dose of no more than 1013, 1012, 1011, 1010, 109, 108, 107, 106, 105, or 104, viral genomes (vg)/kg body weight of the subject.

### Claim 37 (depends on 30)

The method of claim 30, wherein the dose of the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region in the subject systemically at a titer of at least about 1:100, 1:500, 1:10000, 1:50000, or 1:100000.

### Claim 38 (depends on 30)

The method of claim 30, wherein the dose of the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region in the subject systemically at a titer of at least about 1:100, 1:500, 1:10000, 1:50000, or 1:100000, or at a concentration of at least about 0.5 IU/ml, 1 IU/ml, 5 IU/ml, 10 IU/ml, 50 IU/ml, 100 IU/ml, 500 IU/ml, or 1000 IU/ml, as soon as 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240, or 256 hours after treatment.

### Claim 39 (depends on 30)

The method of claim 30, wherein the dose of the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region in the nervous system of the subject, at a titer of at least about 1:100, 1:500, 1:10000, 1:50000, or 1:100000, or at a concentration of at least about 0.5 IU/ml, 1 IU/ml, 5 IU/ml, 10 IU/ml, 50 IU/ml, 100 IU/ml, 500 IU/ml, or 1000 IU/ml, as soon as 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240, or 256 hours after treatment.

### Claim 40 (depends on 30)

The method of claim 30, consisting of administering a single dose of the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region.

### Claim 41 (depends on 30)

The method of claim 30, wherein the subject is immunocompromised.

### Claim 42 (depends on 30)

The method of claim 30, wherein the subject is a newborn infant.

### Claim 43 (depends on 30)

The method of claim 30, wherein the subject is human subject.

### Claim 44 (depends on 30)

The method of claim 30, wherein the subject is an animal subject.

### Claim 45

An adeno-associated virus (AAV) vector that expresses in the central nervous system (CNS) of a subject an immunoglobulin that binds Glycoprotein G of rabies lyssavirus and has neutralizing activity to rabies lyssavirus in host cells exposed to rabies lyssavirus compared to host cells in a subject not administered the AAV vector, wherein the AAV vector is effective for expressing SEQ ID NO:1 connected to the CR57 rabies variable heavy chain region and variable light chain region.

### Claim 46 (depends on 45)

The vector of claim 45, wherein the AAV vector expresses a heavy chain of the CD57 antibody via a single promoter and the AAV vector expresses a light chain of the CD57 antibody via exon skipping induced by furin cleavage.

### Claim 47 (depends on 45)

A pharmaceutical composition comprising the AAV vector of claim 45 and a suitable pharmaceutical excipient.

### Claim 48 (depends on 47)

A method for treating and/or preventing an infection by rabies lyssavirus in a subject in need thereof, the method comprising administering to the subject a dose of the pharmaceutical composition of claim 47.

### Claim 49 (depends on 47)

A kit comprising the pharmaceutical composition of claim 47.
